



NYHA Heart Failure Disease Classifications	
CLASS	DESCRIPTION
Class I	No physical limitation in activity
Class II	Slight limitation in ordinary physical activity, resulting in fatigue, palpitations, dyspnea, or angina
Class III	Marked limitation in activity; clients are comfortable at rest, but less than ordinary activity leads to symptoms.
Class IV	Symptoms are present at rest; any activity leads to increased discomfort

#### Beta Blockers:

Generic Name	Trade Name	Initial Dose	Target Dose	Titration
carvedilol*	Coreg®	3.125 mg BID	Max dose tolerated; not to exceed 25 mg BID (<85 kg) 50 mg BID (>85 kg)	Double dose q 2 weeks (as tolerated)
metoprolol	Lopressor®	12.5 QD	200 mg QD	Double dose q 2 weeks (as tolerated)

#### ACE Inhibitors:

Generic Name	Trade Name	Initial Dose	Target Dose
benazepril	Lotensin®	5-10 mg QD	20-40 mg QD
captopril*	Capoten®	6.25-25 mg TID	150 mg QD
enalapril*	Vasotec®	2.5 mg BID	10-20 mg BID
fosinopril*	Monopril®	5-10 mg QD	20-40 mg QD
lisinopril*	Prinivil/Zestril®	10 mg QD	20-40 mg QD
moexipril	Univasc®	3.75 - 7.5 mg QD	7.5-30 mg QD
quinapril*	Accupril®	5 mg BID	40 mg BID
ramipril**	Altace®	2.5 mg BID	5 mg BID
trandolapril**	Mavik®	1-2 mg QD	2-4 mg QD

#### Angiotensin II Receptor Antagonists:

Generic Name	Trade Name	Initial Dose	Target Dose
candesartan	Atacand®	16 mg QD	8-32 mg QD
irbesartan	Avapro®	150 mg QD	300 mg QD
losartan	Cozaar®	50 mg QD	25-100 mg QD
valsartan	Diovan®	80 mg QD	80-320 mg QD

#### Nitrates & Hydralazine:

Generic Name	Trade Name	Initial Dose	Target Dose
hydralazine	Apresoline®	10 mg QID	50 mg QID
isosorbide dinitrate	Isordil®	5-20 mg Q 6 h	10-40 mg q 6 h

\*FDA approved for heart failure, \*\*FDA approved for heart failure post MI

# Left Ventricular Systolic Dysfunction Heart Failure Algorithm

**Patient Identification**

Name: \_\_\_\_\_

\_\_\_\_\_

In all patients with heart failure



Assessment of LV function



Record EF result \_\_\_\_\_ Date \_\_\_\_\_  
Type of test \_\_\_\_\_



EF < 40%

No

Investigate and treat  
etiology and symptoms



See Diastolic Heart Failure  
Algorithm

Yes

Record ACEI prescribed \_\_\_\_\_  
Starting dose \_\_\_\_\_ Date \_\_\_\_\_  
Target dose \_\_\_\_\_ (see reverse)

ACEI  
not used

Record reason ACEI not used for  
this patient: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
Record alternative meds (dose,  
date): \_\_\_\_\_  
\_\_\_\_\_

Consider  
other meds

Record beta-blocker used: \_\_\_\_\_  
Starting dose \_\_\_\_\_ Date \_\_\_\_\_  
Target dose \_\_\_\_\_ (see reverse)

Digoxin \_\_\_\_\_ dose \_\_\_\_\_ date \_\_\_\_\_  
Diuretic \_\_\_\_\_ dose \_\_\_\_\_ date \_\_\_\_\_  
Spironolactone dose \_\_\_\_\_ date \_\_\_\_\_  
(for NYHA III-IV)  
Other \_\_\_\_\_ dose \_\_\_\_\_

Date last updated: \_\_\_\_\_

Current NYHA Class: \_\_\_\_\_